Baker Bros. Advisors LP Viking Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $1.89 Million - $2.45 Million	-363,980 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $213,166 - $269,876	-40,220 Reduced 9.95%	363,980 $2.05 Million
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $119,184 - $168,688	-20,800 Reduced 4.89%	404,200 $2.35 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $4.12 Million - $8.35 Million	425,000 New	425,000 $7.4 Million

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.